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Current Practice and Perception of Screening for Medication
Adherence in Inflammatory Bowel Disease
Arvind J. Trindade, MD, Donald E. Morisky, ScD, MSPH, ScM, Adam C. Ehrlich, MD,
Andrew Tinsley, MD, and Thomas A. Ullman, MD
Background: Adherence to medication in inflammatory bowel
disease (IBD) improves outcomes. Current practices of screening
for adherence to IBD medications are unknown. The goal of this
study was to determine current practice and perception of screening
for medication adherence among US-based gastroenterologists.
Methods: A survey was mailed electronically to gastroenterologists
whose electronic-mail address was listed in the American College of
Gastroenterology database. Physicians who cared for IBD patients
were invited to answer.
Results: About 6830 surveys were sent to gastroenterologists
nationwide, and 395 physicians who cared for IBD patients
completed the survey. The true response rate is unknown, as the
number of physicians caring for IBD patients in the database is
unknown. About 77% (n=303) of physicians who responded
stated they screen for adherence to medication. Of the 77% of
physicians who screened for adherence, only 19% (n=58) use
accepted measures of screening for adherence (pill counts,
prescription refill rates, or adherence surveys). The remaining
81% used patient interview to screen for adherence, a measure
considered least accepted to determine adherence, as it over-
estimates adherence. The average number of IBD patients observed
in 1 week had no statistical significance in predilection for screening
(P=0.82). Private practice physicians (P=0.05), younger physi-
cians (P=0.03), and physicians with fewer years of experience
(P=0.02) all were more likely to screen. About 95% of responders
thought determining a low adherer to medicine was important
because an intervention can increase adherence.
Conclusions: The majority of gastroenterologists surveyed recog-
nize that adherence to medication is important and improves
outcomes. The majority of physicians in this study are screening for
nonadherence in IBD, but are not using accepted measures for
adherence detection. If this study truly reflects the majority of
physicians nationwide, changing the way physicians screen for
adherence, may detect more low adherers to medication.
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The inflammatory bowel diseases (IBD), Crohn’s disease,and ulcerative colitis are chronic inflammatory dis-
orders of the gastrointestinal tract for which a wide array of
medication treatments are used. These include mesalamine-
based compounds, corticosteroids, thiopurines, methotrexate,
antibiotics, and antitumor necrosis therapies. Adherence to
these medications is essential to prevent flares in these chronic
disorders. Unfortunately, adherence to therapy is suboptimal
in chronic disease,1–4 with IBD being no exception:
nonadherence rates to oral IBD medication have been
reported to be as high as 40% to 72%.1–3
Recently, medical adherence has been called for as a
priority for healthcare reform.4 IBD showcases why this
should be the case. Nonadherence to IBD medications has
both patient-specific and societal implications; it causes
increased morbidity with a greater chance of relapse,
increased disease activity, and a decreased quality of life.5,6
Nonadherence affects society in that it raises healthcare
inpatient and outpatient expenditures by at least 30%,
according to a BlueCross/BlueShield database study.7 In a
UK-based study, higher adherence was associated with
lower healthcare costs and fewer patient visits.8
Screening for nonadherence has the capacity to
identify low adherers, an important first step to remedy
the problem. Once low adherers are identified, the etiology
for nonadherence can be explored before an intervention is
initiated. Current approaches to address nonadherence are
tailored to the etiology but include improving the physi-
cian-patient relationship, individualizing therapy, providing
patient information and support, self-management pro-
grams, and practical memory aids.3
Identifying low adherers, however, can be difficult.
Currently accepted methods to determine adherence include
patient interview, reviewing pharmacy refill data, pill count-
ing, and checking serum or urinary metabolite levels.
Screening for nonadherence can be performed using adher-
ence surveys developed for chronic diseases.9,10 According to
Fletcher et al and many other groups, determining adherence
by patient interview is the least valid way of determining
adherence.11,12 Pill counts and obtaining prescription refill
data are time-intensive measures and not conducive to busy
clinical practice. Adherence surveys, although rarely used, are
more feasible in practice-based settings because of their low
cost and ease of use. The Morisky Medication Adherence
Scale-8 (MMAS-8) adherence scale, which was recently
validated in IBD and is the only validated scale for IBD,
was developed to be nonaccusatory and patient friendly.2
A recent study by our group suggested that gastro-
enterologists are incompletely adept at identifying patients
who are low adherers to medicine. Our study compared
physician perception of adherence with the MMAS-8
survey adherence group that categorizes adherers as low,
medium, or high. Physicians overestimated adherence inCopyright r 2011 by Lippincott Williams & Wilkins
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67% of patients when compared with the results of the
MMAS-8 survey.2 One of the unresolved questions that the
study did not answer was how physicians were determining
adherence in their patients. In fact, the current screening
patterns for nonadherence to IBD medicine amongst
gastroenterologist are unknown. The goal of this study
was to determine current practice and beliefs of medication
adherence screening in IBD in the United States.
METHODS
The study protocol was exempt from the Institutional
Review Board as no identifying information was recorded.
A 10-question survey (Table 1) was mailed electro-
nically to gastroenterologists whose electronic mail (e-mail)
address was listed in the American College of Gastroenter-
ology roster that is publicly available to members.
Physicians, both pediatric and adult, who cared for IBD
patients were invited to answer the survey. It was unknown
which gastroenterologists listed in the database cared for
IBD patients, and thus the survey was sent to every
gastroenterologist with a listed e-mail address in all 50
states. Physicians who did not care for patients with IBD
were asked not to complete the survey; and thus excluded
themselves from the study. The survey was anonymous and
no names, Internet Protocol addresses, or other identifying
information was recorded. The survey, the survey re-
sponses, and data compilation was performed through
Survey Monkey, an online survey company. No compensa-
tion was offered or provided to survey responders.
A 3-month response time was given, and after this
period, the survey was closed. Results were tabulated after
the 3-month period was over. The survey monkey software
added the responses and calculated the overall results.
Surveys were excluded if they were not completely filled out.
Statistical comparisons among binary variables were
made using w2 tests with Pr0.05 considered significant. All
calculations were performed using SPSS 18.0 for Windows
(SPSS, Inc, Chicago, IL).
RESULTS
About 6830 surveys were sent nationwide. This
number excludes e-mails that were not able to be received
TABLE 1. Summary of the 10-Question Survey that was Electronically Mailed to Gastroenterologists and the Responses
Question No. Question Multiple Choice Answer Response (%)
1 What is your sex? (a) Female
(b) Male
29.4
70.6
2 What is your age? (in y) (a) 30–39
(b) 40–49
(c) 50–59
(d) 60–69
(e) 70–79
(f) 80–89
41
26.3
20.8
9.9
1.0
1.0
3 How many years have you been in practice post-
GI training? (If in fellowship select 0)
(a) 0
(b) 1–5
(c) 6–10
(d) 11–19
(e) 20–29
18.7
20.5
11.9
19.2
19.0
4 What is the average number of IBD patients
you care for each week?
(a) 1–5
(b) 6–10
(c) 11–15
(d) 16–20
(e) >21
34.7
38.2
14.2
5.1
7.8
5 Are you in private or academic practice? (a) Private
(b) Academic
52.2
48.1
6 Do you screen for adherence of oral IBD
medication? (able to select more than 1
answer)
(a) No
(b) Yes, with pill counts
(c) Yes, with prescription refill rates
(d) Yes, with adherence surveys
(e) Yes, specific questions (ie, Do you take your
medicine)?
(f) Yes, another source
23.3
1.0
12.4
1.3
71.6
1.6
7 How important is screening for adherence to
IBD medicine?
(a) Very important
(b) Important
(c) Somewhat important
(d) Not important
54.9
33.9
10.1
1.3
8 Improving adherence can improve health-
related outcomes in IBD?
(a) True
(b) False
99.2
0.8
9 Determining a low adherer is important because
an intervention can increase adherence?
(a) True
(b) False
95.2
4.8
10 To date no medication adherence scale has been
validated in IBD. If an adherence scale was
validated in IBD, and was quick and easy to
use, how likely would you be to use it? (In
what percentage of patients)
(a) 100
(b) 75
(c) 50
(d) 25 or less
48.1
26.1
16.5
9.6
GI indicates gastrointestinal; IBD, inflammatory bowel disease.
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because of outdated or expired e-mail addresses, e-mail
accounts not accepting e-mails, and for various other
reasons that resulted in incomplete or absent delivery. Four
hundred and two responses to the survey were completed
for a gross response rate of 6%. A true response rate could
not be calculated as the number of physicians who cared for
IBD patients was unknown. Seven surveys were excluded
for not being completely filled out, leaving 395 surveys for
further analysis.
Table 1 lists the characteristics of the responders.
Characteristics of nonresponders were unavailable in the
database. Overall, 71% of responders were men and 29%
were women. The majority of responders, 41%, were aged 30
to 39 years. There was a wide variation in the number of
years of practice for responders of the survey. There was also
a wide variation in number of patients seen in a week. The
majority of responders, 38%, observed 6 to 10 IBD patients a
week. About 35% observed 5 or less IBD patients a week and
27% observed more than 11 IBD patients a week. The
percentage of responders in private versus academic practice
was about equal, 52% versus 48%, respectively.
In terms of screening behavior, 23% (n=92) of
responders reported that they do not screen for adherence
to oral medications. About 77% (n=303) of the physicians
who responded stated that they screen for adherence to
medication. Of the 77% who screen for adherence, only
19% (n=58) reported use of accepted measures for
screening for adherence (pill counts, prescription refill
rates, or adherence surveys). The remaining 81% used
patient interview to screen for adherence, a measure
considered least accepted to determine adherence.
Statistical tests were used to analyze the obtained data
and are summarized in Table 2. Responders were assessed for
presence of screening (yes vs. no). The number of IBD
patients observed by a physician in 1 week did not affect
whether the physician screened patients for adherence
(P=0.82). Physicians in private practices were more likely
to screen their patients for adherence [relative risk
(RR)=1.66, P=0.05]. The number of years past fellowship
training predicted the presence of screening methods;
physicians still in training or with up to 10 years of
posttraining experience were more likely to screen patients
as compared with physicians with greater than 10 years of
experience (RR=2.16, P=0.004). Similarly, younger physi-
cians were more likely to use an accepted screening method
(up to age 39 y vs. age 40 y or above, RR=1.78, P=0.032).
In this study, physician age correlated with years of
experience. Physician age when compared with years of
experience did not add any additional risk or benefit.
In addition, subgroup analysis showed that there were
a greater number of younger physicians aged 39 years or
below in academic medicine. Therefore, age was not a
confounder and does not explain why private practice
physicians screen more often.
In terms of screening beliefs, 89% of responders
thought screening was very important or important versus
11% who thought screening was somewhat important or
not important. About 99% of responders thought improv-
ing adherence would improve health-related outcomes and
95% of responders thought determining a low adherer to
medicine was important because an intervention could
increase adherence. About 74% of responders would use a
validated adherence survey in practice in a majority of their
patients and 48% of responders stated that they would use
it in every patient.
DISCUSSION
Our results help to elucidate the current practice and
beliefs of screening for medication adherence in IBD,
assuming our survey population is representative of all
physicians who care for patients with IBD. We found that
the majority of physicians surveyed believe that screening
for adherence is important and can change outcomes. In
fact, the majority of physicians stated that they screen for
adherence (77% of physicians). However, of this majority,
very few use accepted methods for determining adherence,
as most used patient interview to screen for adherence.
Patient interview is the simplest form of screening, and
involves asking the patient directly whether he is adherent
to medication. As mentioned earlier, patients often over-
estimate or perhaps misrepresent their adherence, and thus
this is not an accurate method for determining true
adherence. In 1 study in patients with human immunode-
ficiency virus, patient interview had a sensitivity of 14%
and a specificity of 96%.11 Thus, those needing interven-
tions for nonadherence would not be identified by patient
interview. Other studies on patient interview have shown
similar results.12–16 Only 2 studies in IBD have looked at
patient interview for detecting adherence. In 1 study of
patients taking 5-aminosalicylic acid medications for IBD,
patient interview was concordant with urinary drug
measurement in only 66% of patients.17 The other study
is by Hommel et al, in which objective measurement of
adherence was compared with the subjective patient
perception of adherence by the patient through patient
interview. Their group found that patients grossly over-
estimated or overstated adherence. In their cohort of 42
IBD patients, they found that objective nonadherence rates
were 64% for thiopurines and 88% for 5-aminosalicylic
acid compounds; however, subjective nonadherence rates as
per the patients were 10% and 2%, respectively.18 Many
TABLE 2. Statistics for Factors Related to Screening (Based on Questions From Table 1)
Categories of Physicians Examined Relative Risk P
Younger physicians more likely than older physicians (question 2)* 1.78 0.032
Physicians with less years of experience posttraining (question 3)w 2.16 0.004
Number of IBD patients seen per week (question 4)z NA 0.818
Private practice more likely than academic practice (question 5) 1.66 0.047
*Younger physicians defined as 39-y-old or younger. Older physicians defined as 40-y-old or above.
wLess training defined as 10 y postfellowship or less. More training defined as greater than 10 y postfellowship.
zNumber of IBD patients seen per week broken down by 1-5, 6-10, 11-15, 16-21, and Z21.
IBD indicates inflammatory bowel disease; NA, not applicable.
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other studies of patient interview in non-IBD disease
groups have similar sensitivities.12–16 The consensus from
the adherence literature is that this is the least accepted way
of determining adherence in chronic disease12–16; yet, it is
the most popular way to screen in IBD according to our
results.
Pill counts and obtaining prescription refill informa-
tion are more accepted for determining adherence. The
downfall to these measures are that they are time
consuming and not practical in a busy clinical practice.
Adherence surveys are easy to use, accepted as screening
tools for adherence, and do not take excessive time. The
only adherence scale to be validated in IBD is the MMAS-
8.2,19 This scale was developed from the original Morisky
scale.20 The new scale was developed as the earlier scale was
considered accusatory in nature, isolating, and often
evoked defensiveness from patients.21 For example, 1 of
the 4 questions was, “Are you careless about taking your
medicine?” The authors concluded that the MMAS-8 scale
was relatively simple and practical to use in clinical settings,
could identify patients with adherence problems, and could
be used to monitor adherence over the course of the
treatment. Given the ease of use and the patient-friendly
nature of the scale, the MMAS-8 is a convenient scale for
use in IBD (Table 3). According to this survey, close to half
of all responders stated they would use a validated adherence
scale in every patient. An additional quarter of the responders
would use it at least 75% of the time. The MMAS-8 seems
like a tool that physicians would use once it becomes known
that it is already a recently validated tool in IBD.
Of interest, the physicians who were more likely to
screen for nonadherence were those with less than 10 years
of experience, those below 40 years of age, and those in
private practice. It is unclear why these groups are more
likely to screen, and further research is needed to further
clarify these features.
Although nonadherence to medication raises health-
care expenditures and results in worse clinical outcomes, it
is not formally recommended to screen for adherence in
clinical practice and is absent from IBD guidelines.22,23 The
point of screening for adherence is to detect low adherers,
and administer an intervention that results in improved
adherence and consequently in improved outcomes; how-
ever, no study to date has been performed showing
improved outcomes, and may explain why screening for
nonadherence is not formally recommended. Many inter-
ventions are available and have been shown to improve
adherence.3 Examples are improving the physician-patient
relationship, individualizing therapy, providing patient
information and support, self-management programs, or
practical memory aids. Interestingly, improving the physi-
cian-patient relationship may be the most important factor
as a recent systematic review by Jackson et al,24 showed
that no clinical, demographic, or treatment variables
affected adherence. Patient-doctor relationship, physiologi-
cal distress, and patient beliefs about medicine were
important determinants of adherence.
This study suffers the traditional weaknesses of survey
studies which include reactivity (respondents give socially
desirable responses that make them look good or seem to
be what the researcher is looking for), sampling frame
(difficult to access the proper number and type of people
who are needed for a representative sample of the target
population), measurement error (inherent systematic
biases), and errors because of nonresponse (people who
choose to respond on the survey may be different from
those who do not respond, thus biasing the estimates).25 We
were unable to compare characteristics with those who
completed the survey versus those who did not, as
characteristics for nonresponders were not available in the
database. In addition, we chose the survey to have answer
choices that had discrete cut-off points, as opposed to
collecting data in continuous form. This facilitated the ease
of responders to complete the survey. There are limitations
to this style of survey, mainly in that it can attenuate the
relationship between a variable and outcome. In addition,
individual responses may be more similar across categories
than within categories.
In addition, many survey studies traditionally suffer
from low response rate, and thus a low survey accuracy or
sampling bias. However, this notion has been challenged.
It has been assessed whether lower response rates are
TABLE 3. Morisky Medication Adherence Scale-819
No=1 Yes=0
1. Do you sometimes forget to take your IBD pills?
2. People sometimes miss taking their medications for reasons other than forgetting. Thinking over the
past two weeks, were there any days when you did not take your IBD medicine?
3. Have you ever cut back or stopped taking your medication without telling your doctor, because you
felt worse when you took it?
4. When you travel or leave home, do you sometimes forget to bring along your IBD medication?
5. Did you take your IBD medicine yesterday?
6. When you feel like your IBD is under control, do you sometimes stop taking your medicine?
7. Taking medication everyday is a real inconvenience for some people. Do you ever feel hassled about
sticking to your IBD treatment plan?
8. How often do you have difficulty remembering to take all your medications?
(Please circle the correct number)
Never/Rarely 4
Once in a while 3
Sometimes 2
Usually 1
All the time 0
Use of the rMMAS is protected by US copyright laws. Permission for use is required. A license agreement is available from: Donald E. Morisky, ScD,
ScM, MSPH, Professor, Department of Community Health Sciences, UCLA School of Public Health, 650 Charles E. Young Drive South, Los Angeles, CA
90095-1772.
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associated with less unweighted demographic representa-
tiveness of a sample.26 By examining the results of 81
national surveys with response rates varying from 5% to
54% were examined. Surveys with much lower response
rates were only minimally less accurate. Our study had a
gross response rate of 6%, however, this is an under-
estimation as many members of the American College of
Gastroenterology database do not practice clinical IBD,
and thus as per our instructions asked not to complete the
survey. Examples of people who could fall into this
category include physicians or members who are retired,
related careers without patient contact (pathologists), and
physicians who do not see IBD patients in their office.
Thus, the true response rate is in fact much higher.
Overall, the study showed the majority of physicians
surveyed are not using accepted measures to screen for
nonadherence to medication. Cutler and Everett4 wrote
“The bottom line is this: We’ve known for some time that
improved adherence can lead to improvements in health
outcomes and reductions in healthcare spending. What we
haven’t known is where to start.” Screening with the
appropriate available tools may be the place to start if we
can show improved outcomes. A prospective trial is needed
in the future that can evaluate outcomes in those screened
for nonadherence versus those not screened.
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